Carsten Brunn: If I understand the question correctly, is this around ImmTOR or Xork. Just ImmTOR works through the liver, but we have partnerships and all the data we have generated is in liver-directed vectors. But obviously, we do have a partnership with Sarepta and looking at neuromuscular disease, where we also believe that there’s a good rationale why we could use ImmTOR migrate, obviously, as well systemically that hopefully address the question?
Boobalan Pachaiyappan: So the question was not about ImmTOR, it was about Xork but yes, thanks for the color there.
Peter Traber: I can comment on the Xork. So the Xork works through variance of systemic IgG so of the neutralizing antibodies included. So regardless of where the capsid target is, it’s going — as long it’s systemically delivered, it’s going to be intercepted by the neutralizing antibodies. So the Xork enzyme should be active in that situation.
Operator: Next question comes from Uy Ear of Mizuho.
Uy Ear: So I guess the first question is on the MMA study that you guys are ongoing. Just curious to sort of get a better sense of what you’re seeing in terms of patients’ interest in the gene therapy? And I guess my second question is given the completion of the DISSOLVE 1 and DISSOLVE 2 studies, just curious to — curious to see if you can help us understand how to think about R&D for 2023. It looks like the consensus is projecting kind of flat R&D versus 2022. And yes, that’s essentially it.
Carsten Brunn: Great. Yes. I’ll give the first question to Peter, who is obviously intimately involved in the ReMagine trial, which we’re running at a single center at the NIH, Peter?
Peter Traber: Yes, happy to answer that. In terms of the patient interest, we have done a good deal of promotion of the trial through the Organic Acidemia Society, the website for the trial and so forth. And we have gotten a lot of interest both in the U.S. and internationally. But of course, this is a trial where we are sequentially enrolling subjects over time. So it’s not like the trial success is going to be dependent on a very large group of patients interested right at the beginning because we’re going to enroll them sequentially over the course of two years. We have, as you know, the trial is active. It has been since the end of last year. We have enrolled a subject — first subject, and that subject is going through the extensive screening process leading up to treatment. And we don’t have a specific date or timing yet for that, but it’s — the program is moving along with screening and evaluating the first subject.
Carsten Brunn: Great. And Blaine, if you handle the second around R&D expenses.
Blaine Davis: Sure. Yes. So relative to R&D expenses, well, we don’t kind of specifically guide to how to think about future expenses for the organization overall. Let me give a little bit of context. So as you could expect, we continue to have clinical trial expenses associated with the SEL-212 program that will be continuing in 2023. And then we’ll also start to have obviously a decent amount of ramp-up activity associated with the earlier stage pipeline around preclinical activities as well as kind of a number of other sort of R&D-related expenses. So there will start to be a shift in kind of where those R&D expenses are associated on a go-forward basis. We do have a number of kind of early-stage activities and programs as well as the ongoing MMA study that will start to have a shift overall.
